Relief Therapeutics Holding AG (RLFTF)

[elllk]

I will express the same thanks and praise to J.-Belfort and add that sales profits of "85% Europe/ 80% rest of the world" could be extremely significant since Aviptadil (Zyesami) will, relatively speaking, be a good bit cheaper to produce as well as being much easier to distribute to any part of the world including to the rural and remote areas of the world.